Heart Failure Drugs Market

SGLT2 inhibitors are estimated to hold 31.0% of drug class demand in 2026, with HFrEF projected at 54.0% by indication and oral medicines at 82.0% by route. Guideline-directed therapy broadens eligibility across care settings, but comorbidities and access controls slow complete regimen adoption.